Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -234.42% is 189% below its 5-year average of -81.17%, near the low end of its 5-year range (-234.42%–-14.11%).
As of the fiscal period ended Tuesday, June 30, 2026. 105.72% below its 12-month average of -113.95%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -234.42%.
RETURN ON EQUITY (ROE)
-234.42%
RETURN ON EQUITY (ROE) AVG TTM
-113.95%
RETURN ON EQUITY (ROE) AVG 3Y
-101.66%
RETURN ON EQUITY (ROE) AVG 5Y
-81.17%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-105.72%
CURRENT VS 3Y AVG
-130.60%
CURRENT VS 5Y AVG
-188.79%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.20%
median of 532 covered companies
CURRENT VS SECTOR MEDIAN
-483.06%
vs the sector median at left
Entera Bio Ltd.
Market Cap
$125.44M
Return on Equity (ROE)
-234.42%
TTM Avg
-113.95%
3Y Avg
-101.66%
5Y Avg
-81.17%
Market Cap
$123.66M
Return on Equity (ROE)
-663.38%
TTM Avg
-427.48%
3Y Avg
-294.92%
5Y Avg
-251.31%
Market Cap
$122.96M
Return on Equity (ROE)
N/A
TTM Avg
143.89%
3Y Avg
2.05%
5Y Avg
-53.47%
Market Cap
$121.22M
Return on Equity (ROE)
-2.13%
TTM Avg
-45.09%
3Y Avg
-61.80%
5Y Avg
-44.27%
Market Cap
$129.68M
Return on Equity (ROE)
-262.64%
TTM Avg
-45.72%
3Y Avg
-38.99%
5Y Avg
-37.83%
Market Cap
$119.72M
Return on Equity (ROE)
-165.57%
TTM Avg
-146.09%
3Y Avg
30.63%
5Y Avg
465.14%
Market Cap
$117.21M
Return on Equity (ROE)
N/A
TTM Avg
326.93%
3Y Avg
83.50%
5Y Avg
24.39%
Market Cap
$117.11M
Return on Equity (ROE)
-57.47%
TTM Avg
-26.63%
3Y Avg
16.73%
5Y Avg
210.40%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $125.44M | -234.42% | -113.95% | -101.66% | -81.17% |
| Cibus, Inc. (CBUS)vs › | $123.66M | -663.38% | -427.48% | -294.92% | -251.31% |
| NRx Pharmaceuticals, Inc. (NRXP)vs › | $122.96M | N/A | 143.89% | 2.05% | -53.47% |
| enGene Holdings Inc. (ENGN)vs › | $121.22M | -2.13% | -45.09% | -61.80% | -44.27% |
| Health Catalyst, Inc. (HCAT)vs › | $129.68M | -262.64% | -45.72% | -38.99% | -37.83% |
| TuHURA Biosciences, Inc. (HURA)vs › | $119.72M | -165.57% | -146.09% | 30.63% | 465.14% |
| Freenome, Inc. (FRNM)vs › | $132.31M | N/A | N/A | N/A | N/A |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $117.21M | N/A | 326.93% | 83.50% | 24.39% |
| LENZ Therapeutics, Inc. (LENZ)vs › | $117.11M | -57.47% | -26.63% | 16.73% | 210.40% |
| Caribou Biosciences, Inc. (CRBU)vs › | $116.54M | -105.40% | -90.09% | -60.23% | -18.64% |
ROE
-234.4%
ROA
-87.4%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -234.42% |
| 2026-03-31 | -115.81% |
| 2025-12-31 | -87.31% |
| 2025-09-30 | -70.77% |
| 2025-06-30 | -61.44% |
| 2025-03-31 | -52.07% |
| 2024-12-31 | -118.08% |
| 2024-09-30 | -142.25% |
| 2024-06-30 | -100.05% |
| 2024-03-31 | -98.34% |
| 2023-12-31 | -85.59% |
| 2023-09-30 | -159.22% |
| 2023-06-30 | -128.97% |
| 2023-03-31 | -113.86% |
| 2022-12-31 | -111.20% |
| 2022-09-30 | -35.77% |
| 2022-06-30 | -30.57% |
| 2022-03-31 | -23.66% |
| 2021-12-31 | -14.11% |
| 2021-09-30 | -39.84% |
| 2021-06-30 | -34.56% |
| 2021-03-31 | -122.96% |
| 2020-12-31 | -132.93% |
| 2020-09-30 | -194.63% |
| 2020-06-30 | -173.50% |
| 2020-03-31 | -107.02% |
| 2019-12-31 | -90.57% |
| 2019-09-30 | -247.65% |
| 2019-06-30 | -186.64% |
| 2019-03-31 | -119.33% |
| 2018-12-31 | -101.86% |
| 2018-09-30 | -91.76% |
